Advertisement

Osteoporosis International

, 22:2597 | Cite as

Relationship between serum RANKL and RANKL in bone

  • D. M. Findlay
  • G. J. Atkins
Review

Abstract

It is now well accepted that the molecule receptor activator of NFκB ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology. However, interpretation of these data has been elusive, and the relationship between circulating RANKL and RANKL levels in bone is still not clear. This review explores this subject, documenting the possible origins of circulating RANKL and suggesting additional information that is required before serum RANKL levels can provide useful diagnostic or research information.

Keywords

Bone mRNA RANK ligand Serum 

Notes

Conflicts of interest

None.

References

  1. 1.
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602PubMedCrossRefGoogle Scholar
  2. 2.
    Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329–1337PubMedCrossRefGoogle Scholar
  3. 3.
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309PubMedCrossRefGoogle Scholar
  4. 4.
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRefGoogle Scholar
  5. 5.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRefGoogle Scholar
  6. 6.
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson PH, Sawyer RK, Moore AJ, May BK, O'Loughlin PD, Morris HA (2008) Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res 23:1789–1797PubMedCrossRefGoogle Scholar
  8. 8.
    Fazzalari N, Kuliwaba J, Atkins G, Forwood M, Findlay D (2001) The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res 16:1015–1027PubMedCrossRefGoogle Scholar
  9. 9.
    Ikeda T, Utsuyama M, Hirokawa K (2001) Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 16:1416–1425PubMedCrossRefGoogle Scholar
  10. 10.
    Schramek D, Penninger JM (2011) The many roles of RANKL–RANK signaling in bone. Breast and Cancer IBMS BoneKey 8:237–256CrossRefGoogle Scholar
  11. 11.
    Atkins GJ, Welldon KJ, Holding CA, Haynes DR, Howie DW, Findlay DM (2009) The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 30:3672–3681PubMedCrossRefGoogle Scholar
  12. 12.
    Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P (2001) Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:20659–20672PubMedCrossRefGoogle Scholar
  13. 13.
    Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT (1999) Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 265:144–150PubMedCrossRefGoogle Scholar
  14. 14.
    Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR (2005) Osteoprotegerin (OPG) is localized to the Weibel–Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204:714–723PubMedCrossRefGoogle Scholar
  15. 15.
    Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331PubMedCrossRefGoogle Scholar
  16. 16.
    Mueller RJ, Richards RG (2004) Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues. J Mater Sci Mater Med 15:367–372PubMedCrossRefGoogle Scholar
  17. 17.
    Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF (2002) MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res 17:2068–2079PubMedCrossRefGoogle Scholar
  18. 18.
    Kurata K, Heino TJ, Higaki H, Vaananen HK (2006) Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res 21:616–625PubMedCrossRefGoogle Scholar
  19. 19.
    Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, Ahern MJ, Haynes D (2003) Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 38:380–387PubMedCrossRefGoogle Scholar
  20. 20.
    Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM (2001) Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40:623–630CrossRefGoogle Scholar
  21. 21.
    Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438–5445PubMedGoogle Scholar
  22. 22.
    Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367–4370PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang Y, X-l D, Leung P-C, Wong M-S (2009) Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet. Bone 44:46–52PubMedCrossRefGoogle Scholar
  24. 24.
    Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ (2008) RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 23:672–682PubMedCrossRefGoogle Scholar
  25. 25.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149–2157PubMedCrossRefGoogle Scholar
  26. 26.
    Schramek D, Sigl V, Penninger JM (2011) RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22:188–194PubMedCrossRefGoogle Scholar
  27. 27.
    Findlay DM, Chehade M, Tsangari H, Neale S, Hay S, Hopwood B, Pannach S, O'Loughlin P, Fazzalari N (2008) Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther 10:R2Google Scholar
  28. 28.
    Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7:485–496PubMedCrossRefGoogle Scholar
  29. 29.
    Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK (2008) Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 68:5803–5811PubMedCrossRefGoogle Scholar
  30. 30.
    Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R, Austrian Study Group on Normative Values of Bone Metabolism (2003) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32:681–686PubMedCrossRefGoogle Scholar
  31. 31.
    Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A (2003) Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 88:5361–5365PubMedCrossRefGoogle Scholar
  32. 32.
    Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. Jama 292:490–495PubMedCrossRefGoogle Scholar
  33. 33.
    Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M, Nordic Myeloma Study Group (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98:2269–2271PubMedCrossRefGoogle Scholar
  34. 34.
    Wagner D, Fahrleitner-Pammer A (2010) Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help? Wien Med Wochenschr 160:452–457PubMedCrossRefGoogle Scholar
  35. 35.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL (2005) Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 36:727–735PubMedCrossRefGoogle Scholar
  36. 36.
    Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064–1069PubMedCrossRefGoogle Scholar
  37. 37.
    Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of nontraumatic fracture. JAMA 291:1108–1113PubMedCrossRefGoogle Scholar
  38. 38.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Pavlidou V, Koukoulis G, Avramidis A (2008) Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide. Eur J Endocrinol 158:411–415PubMedCrossRefGoogle Scholar
  39. 39.
    Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T (2009) The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab 27:464–470PubMedCrossRefGoogle Scholar
  40. 40.
    Bowsher RR, Sailstad JM (2008) Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand. J Pharm Biomed Anal 48:1282–1289PubMedCrossRefGoogle Scholar
  41. 41.
    Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios LJ, Escobar-Jimenez F, Munoz-Torres M (2005) The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 16:1368–1374PubMedCrossRefGoogle Scholar
  42. 42.
    Vega D, Maalouf NM, Sakhaee K (2007) CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514–4521PubMedCrossRefGoogle Scholar
  43. 43.
    Yamamoto Y, Udagawa N, Matsuura S, Nakamichi Y, Horiuchi H, Hosoya A, Nakamura M, Ozawa H, Takaoka K, Penninger JM, Noguchi T, Takahashi N (2006) Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Endocrinology 147:3366–3374PubMedCrossRefGoogle Scholar
  44. 44.
    Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274:13613–13618PubMedCrossRefGoogle Scholar
  45. 45.
    Hikita A, Yana I, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, Nakamura K, Seiki M, Tanaka S (2006) Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 281:36846–36855PubMedCrossRefGoogle Scholar
  46. 46.
    Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM, Takahashi N (2007) Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol 178:192–200PubMedGoogle Scholar
  47. 47.
    Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, Wu W, Chrysovergis K, Yamada S, Birkedal-Hansen H, Poole AR (2005) The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci 118:147–156PubMedCrossRefGoogle Scholar
  48. 48.
    Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147–154PubMedCrossRefGoogle Scholar
  49. 49.
    Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P (2008) Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes 116:491–495PubMedCrossRefGoogle Scholar
  50. 50.
    Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K, Irahara M (2008) Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J Endocrinol Invest 31:163–168PubMedGoogle Scholar
  51. 51.
    Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Munoz-Gomez J, Ballesta AM (2003) Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 48:824–828PubMedCrossRefGoogle Scholar
  52. 52.
    Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M (2006) The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54:1772–1777PubMedCrossRefGoogle Scholar
  53. 53.
    van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewe RB, Dijkmans BA, Lems WF (2010) Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 69:1623–1628PubMedCrossRefGoogle Scholar
  54. 54.
    Maimoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E, Ohanna F, Cristol JP, Rossi M, Leroux JL (2005) Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Calcif Tissue Int 76:404–411PubMedCrossRefGoogle Scholar
  55. 55.
    Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW (2005) Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf) 62:92–98CrossRefGoogle Scholar
  56. 56.
    Lien G, Ueland T, Godang K, Selvaag AM, Forre OT, Flato B (2010) Serum levels of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study. Pediatr Rheumatol Online J 8:30PubMedCrossRefGoogle Scholar
  57. 57.
    Spelling P, Bonfa E, Caparbo VF, Pereira RM (2008) Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scand J Rheumatol 37:439–444PubMedCrossRefGoogle Scholar
  58. 58.
    Granchi D, Pellacani A, Spina M, Cenni E, Savarino LM, Baldini N, Giunti A (2006) Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. J Bone Joint Surg Am 88:1501–1509PubMedCrossRefGoogle Scholar
  59. 59.
    Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT (2010) Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 29:1155–1161PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  1. 1.Discipline of Orthopaedics and TraumaUniversity of AdelaideAdelaideAustralia
  2. 2.Hanson InstituteAdelaideAustralia

Personalised recommendations